InSite Vision Receives Special Protocol Assessment From The FDA For The DOUBle Phase 3 Clinical Trial Of AzaSite Plus™ And DexaSite™
InSite Vision Incorporated (OTCBB:INSV) today announced that the Company has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of a Phase 3 clinical trial of AzaSite Plus™ (ISV-502) and DexaSite™ (ISV-305) in patients with blepharitis...